Core Viewpoint - The recent approval of the "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" led by Peking University First Hospital, with the participation of Yidu Tech (02158), marks a significant milestone in the company's focus on specialized intelligent diagnosis and treatment [1] Group 1: Company Developments - Yidu Tech's stock rose over 6% and was trading at 5.94 HKD with a transaction volume of 74.37 million HKD [1] - The laboratory will focus on intelligent diagnosis and treatment for metabolic syndrome related to heart and kidney diseases, showcasing Yidu Tech's commitment to advancing specialized healthcare solutions [1] - As a core co-builder of the laboratory, Yidu Tech will integrate its large model technology capabilities into the research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Group 2: Industry Trends - The development of medical artificial intelligence has entered a phase of value verification through practical applications, indicating a shift towards real-world implementation [1] - The establishment of the laboratory exemplifies a collaborative innovation model that integrates industry, academia, and healthcare, highlighting the importance of partnerships in advancing medical technology [1] - Yidu Tech has collaborated with several well-known hospitals in China to build joint laboratories, demonstrating its comprehensive technical capabilities from data governance to model development and system construction [1]

Core Insights - The core focus of the news is on the advancements and recognition of Yidu Technology in the AI healthcare sector, highlighting its participation in international collaborations and contributions to sustainable health development. Group 1: International Collaboration and Recognition - Yidu Technology has joined the Shanghai Cooperation Organization's Economic Platform Health Sustainable Development Working Committee, marking a significant step in international health cooperation [1][6] - CEO Xu Jiming has been elected as the first director of the committee, reflecting the company's technical strength and contributions to the industry [6] - Yidu Technology was appointed as a vice-chair unit of the China Internet Association's Smart Healthcare Working Committee, aiming to promote the development of smart healthcare [9] Group 2: Academic and Research Initiatives - Founder and Chairman Gong Rujing has been appointed as a member of the Advisory Committee of the Hong Kong City University Digital Medicine Research Institute, recognizing her efforts in integrating AI and big data in healthcare [2] - Yidu Technology has established a practice base with Tsinghua University's School of Public Health, resulting in 11 research outputs and advancements in key technologies [17] Group 3: Innovation and Industry Development - At the 2025 China Social Medical New Ecology Conference, CEO Xu Jiming emphasized the need for non-public healthcare to transition from resource competition to value and experience competition, proposing three key areas for enhancing core competitiveness [15] - Yidu Technology shared its experiences in AI-driven clinical trials at the AI + Drug Development Salon, focusing on improving clinical trial efficiency and data quality [16] - The company participated in the China and International Development Forum, discussing innovative digital health cooperation models [11]

Core Viewpoint - The Hong Kong stock market has shown significant strength in early 2026, particularly in the AI healthcare sector, with companies like Yidu Tech experiencing notable stock price increases due to positive market expectations and supportive policies [1][2]. Group 1: Company Performance - Yidu Tech achieved a three-day stock price increase from January 2 to January 6, 2026, with a closing price of 5.66 HKD on January 6, reflecting a cumulative rise of over 8% [1]. - The company has been recognized as one of the first partners in the Henan Province National Artificial Intelligence Application Pilot Base (medical field), further solidifying its core advantages in AI healthcare technology [1]. Group 2: Industry Trends - The AI healthcare sector is experiencing strong overall performance driven by favorable policies, including two recent initiatives from Beijing aimed at promoting AI applications in healthcare from 2026 to 2027 [1]. - The "Action Plan" released by Beijing outlines a vision for widespread application of AI technology across the entire healthcare process by 2027, enhancing the quality of medical services for the public [1]. - Institutions are optimistic about the growth potential of the AI healthcare industry, anticipating that the synergy between policy support and clinical demand will accelerate the implementation of AI healthcare technologies [2].

呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 2,500,000,000 | | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有 ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Non-registered holders(Note 1) Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong ...

Yidu Tech Inc. 醫渡科技有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock code 股份代號：2158) N O T I F I C AT I O N L E T T E R 通 知 信 函 30 December 2025 Dear Registered Shareholders, Yidu Tech Inc. (the "Company") – Notice of Publication of 2026 Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limite ...

（於開曼群島註冊成立的有限公司） (incorporated in the Cayman Islands with limited liability) Stock code 股份代號: 2158 2025/26 中期報告 Interim Report Yidu Te ch In c. 醫渡科技有限公 司 Interim Report 2025/26 中期報告 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 5 | | 業務回顧 | 6 | | 管理層討論及分析 | 14 | | 企業管治及其他資料 | 19 | | 中期財務資料審閱報告 | 33 | | 中期簡明合併綜合收益表 | 35 | | 中期簡明合併資產負債表 | 37 | | 中期簡明合併權益變動表 | 39 | | 中期簡明合併現金流量表 | 40 | | 中期簡明合併財務資料附註 | 41 | | 釋義 | 77 | 公司資料 執行董事 宮盈盈女士 （董事長） 徐濟銘先生 （首席執行官） 封曉瑛女士 謝麗女士 非執行董事 曾鳴先生 獨立非執行董事 馬維英博士 潘蓉容女士 張林琦教授 審核委員會 潘蓉容女士 （主席 ...

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Provincial Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic move in the development of AI in healthcare in China [1][3]. Group 1: Strategic Partnerships and Collaborations - Yidu Technology is positioned as a "core co-builder" of national medical AI innovation, actively participating in the construction of two national AI pilot bases in Beijing and Henan [1][4]. - The collaboration includes partnerships with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI [3][4]. Group 2: Objectives and Services of the Pilot Base - The National AI Application Pilot Base aims to provide comprehensive pilot services for medical AI products, including algorithm validation, clinical evaluation, and compliance declaration, to accelerate the industrialization of innovative results [3][4]. - Yidu Technology will focus on integrating AI with traditional Chinese medicine, leveraging its expertise in medical data governance and clinical research to support the development of intelligent applications in this field [4][5]. Group 3: Technological Capabilities and Achievements - Yidu Technology has developed the "AI Medical Brain" YiduCore, which has processed nearly 7 billion authorized medical records and collaborates with over 10,000 hospitals, providing a solid foundation for AI model training and optimization [5]. - The company emphasizes its commitment to independent innovation and aims to leverage the pilot base as a strategic support to meet regional development needs while contributing to the "Healthy China 2030" initiative [5].

Core Viewpoint - Yidu Technology has been invited to participate in the Henan Health Industry Development Conference and has signed on as one of the first partners of the National Artificial Intelligence Application Pilot Base (Medical Direction), marking a strategic expansion in the AI healthcare sector [1][3]. Group 1: Strategic Partnerships and Initiatives - The establishment of the National AI Application Pilot Base in Zhengzhou is a key initiative for Henan Province to implement national health strategies and develop the future health industry [3]. - Yidu Technology is collaborating with major tech companies like Baidu and Alibaba, as well as local medical institutions, to create a synergistic ecosystem that integrates technology, data, clinical applications, and AI in healthcare [3][4]. Group 2: Technological Capabilities and Innovations - Yidu Technology's proprietary "AI Medical Brain" YiduCore has processed nearly 7 billion authorized medical records, covering over 10,000 hospital partnerships, providing a solid foundation for AI model training and clinical insights [5]. - The company aims to leverage its experience in AI and data governance to support the integration of AI with traditional Chinese medicine, enhancing the quality of healthcare services in the region [4][5]. Group 3: Future Development and Goals - Yidu Technology plans to continue its focus on independent innovation and align its AI research and implementation with regional development needs, contributing to the "Healthy China 2030" initiative [5].

消息面上，医渡科技近期在行业认可与国际合作领域捷报频传。在香港城市大学数码医学研究院周年大 会上，公司创始人、董事长宫如璟女士获聘为该研究院顾问委员会成员，彰显行业尤其是学界对医渡科 技及战略掌舵人宫如璟女士在AI医疗领域创新实践的认可与信任。 12月19日，医渡科技(02158)公告显示，当日以每股5.23港元的价格回购9.35万股，回购金额约49万港 元。12月以来，公司已回购11次，累计回购约344万股，总金额超1740万港元。以真金白银持续夯实市 场信心，彰显医渡科技对自身发展前景的坚定看好。 近年来，医渡科技的国际化战略布局稳步推进，业务和客户网络已拓展至全球六个地区。通过与当地政 府部门、医疗机构及科研院所深度协同，构建起了成熟的本土化合作生态，研发的智能化解决方案已广 泛落地于传染病监测预警、全民人口健康管理、AI辅助诊疗、个性化健康管理等关键领域，持续以科 技力量赋能全球健康事业发展。 同时值得关注的是，医渡科技在国际多边合作舞台实现重要突破：上海合作组织国家多功能经贸平台 (上合家园)卫生可持续发展工作委员会近期正式成立，医渡科技成功入选组织成员单位;公司联合创始 人、CEO徐济铭当选委员会 ...